UGN-104

Drug identity checked against registry records

Also recorded as UGN-104 (mitomycin) for pyelocalyceal solution

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial CancerNCT06774131URGNPhase 3Recruiting2027-03Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.